Filters








129 Hits in 7.3 sec

Donepezil effects on sources of cortical rhythms in mild Alzheimer's disease: Responders vs. Non-Responders

Claudio Babiloni, Emanuele Cassetta, Gloria Dal Forno, Claudio Del Percio, Florinda Ferreri, Raffaele Ferri, Bartolo Lanuzza, Carlo Miniussi, Davide V. Moretti, Flavio Nobili, Roberto D. Pascual-Marqui, Guido Rodriguez (+4 others)
2006 NeuroImage  
Katiuscia Sosta for their precious help in the development of the present study. We thank also Prof. Fabrizio Eusebi for his continuous support.  ...  We have no conflict of interest with pharmaceutical companies.  ...  It should be remarked that none of those papers addressed the specific aim of the present study and focused on the long-term effects of donepezil on cortical EEG rhythms in AD subjects who responded vs  ... 
doi:10.1016/j.neuroimage.2006.02.015 pmid:16600641 fatcat:nhr4o7yngzc6ddrnhfuccudwjm

Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics

Ramón Cacabelos
2007 Neuropsychiatric Disease and Treatment  
Donepezil is the leading compound for the treatment of Alzheimer's disease (AD) in more than 50 countries.  ...  Although donepezil represents a non cost-effective treatment, most studies convey that this drug can provide a modest benefit on cognition, behavior, and activities of the daily living in both moderate  ...  Donepezil in Alzheimer's disease Most clinical trials with donepezil in AD during the past 10 years have been performed in patients with mild-to-moderate dementia (mAD) (Rogers et al 1996 (Rogers et al  ... 
pmid:19300564 pmcid:PMC2654795 fatcat:rurc64sbffd2dkn4u44ls4lkqe

Resting state cortical EEG rhythms in Alzheimer's disease [chapter]

Fabrizio Vecchio, Claudio Babiloni, Roberta Lizio, Fabrizio De Vico Fallani, Katarzyna Blinowska, Giulio Verrienti, Giovanni Frisoni, Paolo M. Rossini
2013 Supplements to Clinical Neurophysiology  
This review provides an overview of the studies on resting state eyes closed EEG rhythms recorded in amnesic mild cognitive impairment (MCI) and AD subjects.  ...  In this line, digital electroencephalography (EEG) allows non-invasive analysis cortical neuronal synchronization as revealed by resting state brain rhythms.  ...  On the other hand, the effects of AcetylCholinesterase inhibitors such as tetrahydroaminoacridine and donepezil were tested.  ... 
doi:10.1016/b978-0-7020-5307-8.00015-6 pmid:24053043 fatcat:efdzlz2hkfb5dkelrj2ztqf7g4

Personalized Management and Treatment of Alzheimer's Disease

Ramón Cacabelos, Vinogran Naidoo, Olaia Martínez-Iglesias, Lola Corzo, Natalia Cacabelos, Rocío Pego, Juan C. Carril
2022 Life  
Alzheimer's disease (AD) is a priority health problem with a high cost to society and a large consumption of medical and social resources.  ...  The implementation of pharmacogenetics in clinical practice can help optimize the limited therapeutic resources available to treat AD and personalize the use of anti-dementia drugs, in combination with  ...  Acknowledgments: The authors would like to thank their collaborators at the International Center of Neuroscience and Genomic Medicine for technical assistance.  ... 
doi:10.3390/life12030460 pmid:35330211 pmcid:PMC8951963 fatcat:svabmi4wdrdyzeswd5ywxencii

What Electrophysiology Tells Us About Alzheimer's Disease: A Window into the Synchronization and Connectivity of Brain Neurons

Claudio Babiloni, Katarzyna Blinowska, Laura Bonanni, Andrej Cichocki, Willem De Haan, Claudio del Percio, Bruno Dubois, Javier Escudero, Alberto Fernández, Giovanni Frisoni, Bahar Guntekin, Mihaly Hajos (+29 others)
2019 Neurobiology of Aging  
However, current international guidelines do not endorse the use of electroencephalographic (EEG)/magnetoencephalographic (MEG) biomarkers in clinical trials performed in patients with Alzheimer's disease  ...  and patients, to probe the effects of AD neuropathology (i.e., brain amyloidosis, tauopathy, and neurodegeneration) on neurophysiological mechanisms underpinning neural excitation/inhibition and neurotransmission  ...  of Alzheimer's disease (AD) at the preclinical, prodromal (with objective mild cognitive impairment (MCI) but with aut onomy substantially preserved), and overt dementia stages, based on in-vivo fluid  ... 
doi:10.1016/j.neurobiolaging.2019.09.008 pmid:31739167 fatcat:4qovqzkklfduvane3tuttfnfem

Sirtuins in Alzheimer's Disease: SIRT2-Related GenoPhenotypes and Implications for PharmacoEpiGenetics

Ramón Cacabelos, Juan Carril, Natalia Cacabelos, Aleksey Kazantsev, Alex Vostrov, Lola Corzo, Pablo Cacabelos, Dmitry Goldgaber
2019 International Journal of Molecular Sciences  
Sirtuins are components of the epigenetic machinery, which is disturbed in Alzheimer's disease (AD), contributing to AD pathogenesis.  ...  The integration of SIRT2 and APOE variants in bigenic clusters yields 18 haplotypes.  ...  Conflicts of Interest: This article did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The authors declare no conflict of interest.  ... 
doi:10.3390/ijms20051249 fatcat:3hhdssko2rbszpyb4iv4x3le4e

Alzheimer's Disease: Risk Factors and Preventive Strategies [chapter]

Joann T. Tschanz, John C. S. Breitner
2010 Principles and Practice of Geriatric Psychiatry  
365, 366 normal pressure hydrocephalus 130 Parkinson's disease 130 galantamine 305 Alzheimer's disease 296-297 cognitive benefits 305 donepezil comparison 306 dosing 305, 314 effect on brain function  ...  -369 neuropsychiatric effects 307-308, 318-319 non-responders 306 as part of rehabilitation 814 prescribing and monitoring 306-307 rationale for 304 selection/choice 307 side effects 304-305, 314  ... 
doi:10.1002/9780470669600.ch47 fatcat:r3yhydwz5zgzlgr7fxehof64sm

Imaging Markers of Progression in Parkinson's Disease

Antonio P Strafella, Nico I. Bohnen, Nicola Pavese, David E Vaillancourt, Thilo van Eimeren, Marios Politis, Alessandro Tessitore, Christine Ghadery, Simon Lewis
2018 Movement Disorders Clinical Practice  
are required to establish a breakthrough in neuroprotective or disease-modifying therapeutics.  ...  Parkinson's disease (PD) is the second-most common neurodegenerative disorder after Alzheimer's disease; however, to date, there is no approved treatment that stops or slows down disease progression.  ...  In contrast, conversion to dementia in PD might depend on non-dopaminergic, cholinergic and more posterior cortical dysfunctions 27 .  ... 
doi:10.1002/mdc3.12673 pmid:30637278 pmcid:PMC6277366 fatcat:mseo6ql3xjfh7b56akm6qpdff4

VII Congresso Sindem: Italian Association for the study of Dementia linked to the Italian Neurological Society (SIN)

Vincenzo Bonavita, Carlo Caltagirone, Claudio Mariani, Alessandro Padovani, Elio Scarpini, Sandro Sorbi, Daniela Galimberti
2012 Journal of Alzheimer's Disease  
Abstracts 43 Diffusion MRI Since the fi rst applications to AD, DT-MRI has shown the ability to detect microscopic WM abnormalities (FA and MD changes), mainly in the corpus callosum, temporal, frontal  ...  Conclusions: In LBD, the delta source of cortical EEG rhythms in parieto-occipital regions could be related to a "functional lesion" in regions processing visuo-spatial information.  ...  Perfusion SPECT with 99 Tc-ethylene cystine dimer showed hypoperfusion in the frontotemporal Abstracts 64 Aim: To map the distributed sources of cortical EEG rhythms in LBD respect to AD.  ... 
doi:10.3233/jad-2012-129000 pmid:22398403 fatcat:zebkyxd3zzat7gsq4vu3eq7zci

Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer's disease: a systematic review of symptom-general and –specific lesion patterns

Yaojing Chen, Mingxi Dang, Zhanjun Zhang
2021 Molecular Neurodegeneration  
Different NPSs occur in different disease stages of AD, but most symptoms appear in the preclinical AD or mild cognitive impairment stage and develop progressively.  ...  AbstractNeuropsychiatric symptoms (NPSs) are common in patients with Alzheimer's disease (AD) and are associated with accelerated cognitive impairment and earlier deaths.  ...  Acknowledgements We are grateful to Kewei Chen (Banner Alzheimer's Institute) and Chuansheng Chen (University of California, Irvine) for helpful comments on earlier version of this review.  ... 
doi:10.1186/s13024-021-00456-1 pmid:34099005 pmcid:PMC8186099 fatcat:uoiqeal2krfwxnmtnb5bjrw7re

Diagnosis of Alzheimer's Disease from EEG Signals: Where Are We Standing?

Justin Dauwels, Francois Vialatte, Andrzej Cichocki
2010 Current Alzheimer Research  
This paper reviews recent progress in the diagnosis of Alzheimer's disease (AD) from electroencephalograms (EEG).  ...  In this paper, several state-of-the-art pre-processing techniques are outlined, for example, based on blind source separation and other non-linear filtering paradigms.  ...  One of the major effects is EEG "slowing"; many studies have shown that Mild Cognitive Impairment (MCI) and Alzheimer's disease (AD) causes EEG signals to slow down (see, e.g., [52, 53, 54, 55, 56, 57  ... 
doi:10.2174/1567210204558652050 fatcat:ahfknenhb5hmlkp7mkglxtwvum

Imaging the Alzheimer Brain

J. Wesson Ashford, Ahmad Salehi, Ansgar Furst, Peter Bayley, Giovanni B. Frisoni, Clifford R. Jack Jr, Osama Sabri, Maheen M. Adamson, Kerry L. Coburn, John Olichney, Norbert Schuff, Daniel Spielman (+14 others)
2011 Journal of Alzheimer's Disease  
MCI 0.57 Normal vs. Mild AD 0.15 MCI vs. Mild AD 0.20 p-value P-Tau comparison 33 vs. 34 0.07 33 vs. 44 0.67 34 vs. 44 0.99 Normal vs. MCI 0.05 Normal vs. Mild AD <0.01 MCI vs.  ...  ., Effects of Hypoperfusion in Alzheimer's Disease [86]. Shin et al., The Merits of FDDNP-PET Imaging in Alzheimer's [32]. Jensen et al., Research towards tau imaging ).  ... 
doi:10.3233/jad-2011-0073 pmid:21971448 pmcid:PMC3760773 fatcat:ppczzkpe6rb5tanbygwnzgyr3m

Diagnosis of Alzheimers Disease from EEG Signals: Where Are We Standing?

J. Dauwels, F. Vialatte, A. Cichocki
2010 Current Alzheimer Research  
This paper reviews recent progress in the diagnosis of Alzheimer's disease (AD) from electroencephalograms (EEG).  ...  In this paper, several state-of-the-art pre-processing techniques are outlined, for example, based on blind source separation and other non-linear filtering paradigms.  ...  One of the major effects is EEG "slowing"; many studies have shown that Mild Cognitive Impairment (MCI) and Alzheimer's disease (AD) causes EEG signals to slow down (see, e.g., [52, 53, 54, 55, 56, 57  ... 
doi:10.2174/156720510792231720 pmid:20455865 fatcat:feusoo2h5jbsnpgczzel4ljwi4

Neuroimaging of Parkinson's disease: Expanding views

Carol P. Weingarten, Mark H. Sundman, Patrick Hickey, Nan-kuei Chen
2015 Neuroscience and Biobehavioral Reviews  
Advances in molecular and structural and functional neuroimaging are rapidly expanding the complexity of neurobiological understanding of Parkinson's disease (PD).  ...  Neuropathology of PD will be discussed centered on Braak's staging of PD, which describes the progression of pathological abnormalities in regions throughout the brain (section 2.3).  ...  The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Neurological Disorders and Stroke or the National Institutes of  ... 
doi:10.1016/j.neubiorev.2015.09.007 pmid:26409344 pmcid:PMC4763948 fatcat:66ruxnmpyjdoplebvahzyibydq

Prevention approaches in a preclinical canine model of Alzheimer's disease: benefits and challenges

Paulina R. Davis, Elizabeth Head
2014 Frontiers in Pharmacology  
Aged dogs spontaneously develop many features of human aging and Alzheimer's disease (AD) including cognitive decline and neuropathology.  ...  However, overall, using the dog as a preclinical model for testing preventive approaches for AD may complement work in rodents and non-human primates.  ...  In particular, AD patients with mild to moderate dementia who were treated with 80 mg/day atorvastatin had significantly improved scores on one measure of cognition Alzheimer's Disease Assessment Scale-Cognitive  ... 
doi:10.3389/fphar.2014.00047 pmid:24711794 pmcid:PMC3968758 fatcat:caiie5cfbfccrg7v3e35wwt3mq
« Previous Showing results 1 — 15 out of 129 results